Phase III trials were paused this week to investigate a “potentially unexplained illness” in one of the trial participants. Pascal Soriot, AstraZeneca’s CEO, wouldn’t confirm speculation on what the illness is. “We don’t know if it’s transverse myelitis… We don’t know what the final diagnosis is,” Soriot was reported as saying in The Guardian. He added that he believes the vaccine trial is still on track “for having a set of data that we would submit before the end of the year.”